Replimune Posts Q1 Loss, Appoints Chief Commercial Officer Ahead of TUDRIQEV Launch
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune reported fiscal Q1 2027 results with a reduced net loss and named Michelle DiNapoli as Chief Commercial Officer as it prepares to launch TUDRIQEV within 60 days.
Key Events · Earnings and Guidance · REPL
-
Q1 Net Loss Narrows
Net loss was $69.8M for the quarter ended June 30, 2026, compared to $86.7M in the prior-year period, driven by lower R&D and SG&A expenses.
-
Cash Runway Extended
Cash and short-term investments totaled $195.3M as of June 30, 2026, plus $141.0M in net proceeds from the August stock issuance, funding operations for greater than twelve months.
-
Chief Commercial Officer Appointed
Michelle DiNapoli, formerly of Deciphera Pharmaceuticals, will join as Chief Commercial Officer effective August 18, 2026, bringing over 25 years of oncology commercialization experience.
-
TUDRIQEV Launch Within 60 Days
Following FDA accelerated approval on August 6, 2026, the company expects to have TUDRIQEV in the market within 60 days.
Analysis · REPL · Life Sciences
In its first quarterly report since FDA approval, Replimune posted a narrower net loss of $69.8M versus $86.7M a year ago, with cash of $195.3M plus $141M in net proceeds from the recent offering extending runway beyond twelve months. The appointment of Michelle DiNapoli as Chief Commercial Officer, effective August 18, fills a critical role as the company prepares to launch TUDRIQEV within 60 days. The combination of a commercial-stage transition, a key hire, and a confirmed cash runway makes this a notable update for investors.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REPL was trading at $14.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $1.50 to $15.71. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.